Mefloquine--its 20 years in the Thai Malaria Control Program.

Simple item page
dc.contributor.authorWongsrichanalai, Chansudaen_US
dc.contributor.authorPrajakwong, Somsaken_US
dc.contributor.authorMeshnick, Steven Ren_US
dc.contributor.authorShanks, G Dennisen_US
dc.contributor.authorThimasarn, Krongthongen_US
dc.date.accessioned2009-05-27T15:02:06Z
dc.date.available2009-05-27T15:02:06Z
dc.date.issued2004-06-05en_US
dc.descriptionThe Southeast Asian Journal of Tropical Medicine and Public Health.en_US
dc.description.abstractDue to the deteriorating efficacy of sulfadoxine-pyrimethamine (SP or Fansidar), from the mid-1970s the Thai Malaria Control Program was actively involved in testing potential replacement drugs to be used as the primary therapy for falciparum malaria in Thailand. In 1983, a large-scale field trial of mefloquine, a long-acting antimalarial drug known for its efficacy against chloroquine- and SP-resistant Plasmodium falciparum, was initiated on the Thai-Cambodian border. The study enrolled over 60,000 patients and eventually led to the formal establishment of mefloquine as the first line drug for the treatment of uncomplicated falciparum malaria in the country. Mefloquine has played a significant role in the control of malaria in Thailand for the past two decades, initially in combination with SP, then by itself, and currently in selected areas as a partner drug in the combination therapy with artesunate. Thailand is the country with the most experience in the use of this drug in a malaria control program. We present here a review of mefloquine's pharmacology and usage in Thailand.en_US
dc.description.affiliationUS Army Medical Component, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand. chansuda@bangkok.th.comen_US
dc.identifier.citationWongsrichanalai C, Prajakwong S, Meshnick SR, Shanks GD, Thimasarn K. Mefloquine--its 20 years in the Thai Malaria Control Program. The Southeast Asian Journal of Tropical Medicine and Public Health. 2004 Jun; 35(2): 300-8en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/31743
dc.language.isoengen_US
dc.source.urihttps://www.tm.mahidol.ac.th/seameo/2004_35_2/12-3209.pdfen_US
dc.subject.meshAnimalsen_US
dc.subject.meshAntimalarials --adverse effectsen_US
dc.subject.meshCommunicable Disease Controlen_US
dc.subject.meshDrug Combinationsen_US
dc.subject.meshDrug Resistanceen_US
dc.subject.meshHumansen_US
dc.subject.meshMalaria, Falciparum --drug therapyen_US
dc.subject.meshMefloquine --adverse effectsen_US
dc.subject.meshPlasmodium falciparum --drug effectsen_US
dc.subject.meshProgram Evaluationen_US
dc.subject.meshPyrimethamine --pharmacologyen_US
dc.subject.meshSulfadoxine --pharmacologyen_US
dc.subject.meshThailand --epidemiologyen_US
dc.titleMefloquine--its 20 years in the Thai Malaria Control Program.en_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
300.pdf
Size:
101.15 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Southeast Asian Journal of Tropical Medicine and Public Health